↓ Skip to main content
What is this page? Embed badge

Melanoma

Overview of attention for book
Cover of 'Melanoma'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Melanoma
  3. Altmetric Badge
    Chapter 2 Melanoma Epidemiology and Prevention
  4. Altmetric Badge
    Chapter 3 Methods of Melanoma Detection.
  5. Altmetric Badge
    Chapter 4 Melanoma: Clinical Presentations.
  6. Altmetric Badge
    Chapter 5 Principles of Melanoma Staging
  7. Altmetric Badge
    Chapter 6 Surgical Management of Melanoma
  8. Altmetric Badge
    Chapter 7 Adjuvant Therapy of Melanoma
  9. Altmetric Badge
    Chapter 8 Chemotherapy for Melanoma
  10. Altmetric Badge
    Chapter 9 Checkpoint Blockade for the Treatment of Advanced Melanoma
  11. Altmetric Badge
    Chapter 10 Targeted Therapy for Melanoma
  12. Altmetric Badge
    Chapter 11 Treatment of Melanoma CNS Metastases
  13. Altmetric Badge
    Chapter 12 Treatment of Uveal Melanoma
  14. Altmetric Badge
    Chapter 13 Mucosal Melanoma: Epidemiology, Biology and Treatment
  15. Altmetric Badge
    Chapter 14 Acral Lentiginous Melanoma
  16. Altmetric Badge
    Chapter 15 Pediatric Melanoma and Atypical Melanocytic Neoplasms
  17. Altmetric Badge
    Chapter 16 Novel Treatments in Development for Melanoma
Attention for Chapter 10: Targeted Therapy for Melanoma
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
128 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Targeted Therapy for Melanoma
Chapter number 10
Book title
Melanoma
Published in
Cancer treatment and research, January 2016
DOI 10.1007/978-3-319-22539-5_10
Pubmed ID
26601866
Book ISBNs
978-3-31-922538-8, 978-3-31-922539-5
Authors

Deborah J. L. Wong, Antoni Ribas

Abstract

Vemurafenib and dabrafenib, two potent tyrosine kinase inhibitors (TKIs) of the BRAF(V600E) kinase, are highly effective in the treatment of a BRAF (V600) -mutant metastatic melanoma. These are selective type I inhibitors (functional against the active conformation of the kinase) of the RAF kinases, which are key players in the mitogen-activated protein kinase (MAPK) pathway. BRAF (V600) mutations are present in approximately 7 % of all cancers, including high frequencies of mutations reported in 50 % of advanced melanomas and 100 % of hairy cell leukemias. As with most targeted therapies, resistance to BRAF inhibitors is an issue, and mechanisms of resistance are varied. Combining BRAF inhibitors with MEK inhibitors such as trametinib delays the development of resistance. Rationally combining targeted therapies to address the mechanism of resistance or combining BRAF inhibitors with other effective therapies such as immunotherapy may result in further improvement in outcomes for patients.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 128 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 16%
Student > Bachelor 19 15%
Researcher 17 13%
Other 8 6%
Student > Master 8 6%
Other 17 13%
Unknown 39 30%
Readers by discipline Count As %
Medicine and Dentistry 28 22%
Biochemistry, Genetics and Molecular Biology 19 15%
Agricultural and Biological Sciences 9 7%
Immunology and Microbiology 5 4%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Other 18 14%
Unknown 44 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2016.
All research outputs
#18,434,182
of 22,837,982 outputs
Outputs from Cancer treatment and research
#125
of 165 outputs
Outputs of similar age
#285,487
of 395,128 outputs
Outputs of similar age from Cancer treatment and research
#17
of 22 outputs
Altmetric has tracked 22,837,982 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 165 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,128 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.